RUNX1 and cancer: To examine whether the absence of RUNX1 in the cancer cells affects cancer cell-driven hepatocyte modifications in vivo, we stained specimens that were generated from our previous publication [32] with PARP-1, ARP2/3, or E-cadherin antibody.